GlassScriptPhysician profile
Jeffrey Lee Culpepper
NPI 1245222637
$4,415.06
in general payments reported to CMS, 2019-2025
28 companies · $45.00 in 2025
The $45.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.75 · 2021: $743 · 2022: $1,572 · 2023: $1,772 · 2024: $255 · 2025: $45.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.99 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $683.20 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $610.63 | 2021-2025 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $512.79 | 2021-2024 | |
| Abbvie INC. | $450.24 | 2021-2023 | Vraylar, Ubrelvy |
| Amgen INC. | $380.00 | 2021-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $276.70 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Almatica Pharma LLC | $271.80 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Pfizer INC. | $229.10 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $137.51 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $130.06 | 2023-2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $114.04 | 2021-2023 | Seglentis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.81 | 2021-2022 | |
| Glaxosmithkline, LLC. | $97.73 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.68 | 2022 | |
| Shield Therapeutics INC | $53.40 | 2022-2023 | Accrufer |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $37.98 | 2022 | |
| Abbott Laboratories | $32.18 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $27.17 | 2021 | |
| Boston Scientific Corporation | $24.64 | 2024 | |
| Medtronic, INC. | $24.57 | 2024 | Intellis Adaptivestim |
| Daiichi Sankyo INC. | $23.87 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.93 | 2021 | |
| Allergan, INC. | $21.82 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.82 | 2021 | |
| Ethicon US, LLC | $13.90 | 2022 | |
| Currax Pharmaceuticals LLC | $13.86 | 2024 | Contrave, Onzetra Xsail |
| Novartis Pharmaceuticals Corporation | $13.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Culpepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.